预约演示
更新于：2026-04-02
Estriol
雌三醇
更新于：2026-04-02
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24O3 |
InChIKeyPROQIPRRNZUXQM-ZXXIGWHRSA-N |
CAS号50-27-1 |
关联
39
项与 雌三醇 相关的临床试验NCT06873971
Effects of Erbium:YAG Laser Combined With Vaginal Estriol Therapy in Postmenopausal Women With Genitourinary Syndrome of Menopause: A Protocol for a Randomised, Double-blind Controlled Trial
ACTRN12625000085471
Safety and Efficacy of the Estriol Eluting Vaginal Pessary (E-Leviate) to Treat Pelvic Organ Prolapse in Postmenopausal Women with Symptomatic Pelvic Organ Prolapse.
ChiCTR2500097448
A randomized controlled trial of platelet-rich plasma therapy for genitourinary syndrome of menopause.
100 项与 雌三醇 相关的临床结果
登录后查看更多信息
100 项与 雌三醇 相关的转化医学
登录后查看更多信息
100 项与 雌三醇 相关的专利（医药）
登录后查看更多信息
7,243
项与 雌三醇 相关的文献（医药）2026-05-01MOLECULAR AND CELLULAR ENDOCRINOLOGY
2-Hydroxyestradiol regulates extracellular matrix deposition through estrogen receptor beta activation in airway smooth muscle cells
Article
作者: Kumar, Ashish ; Prakash, Y S ; Sathish, Venkatachalem ; Pabelick, Christina M ; Reza, Mohammad Irshad ; Layek, Buddhadev ; Ambhore, Nilesh Sudhakar ; Balraj, Premanand ; Hawse, John R ; Thompson, Michael A ; Banerjee, Anurag
Airway remodeling in asthma is characterized by increased extracellular matrix (ECM) production and deposition by airway smooth muscle (ASM) cells. Existing studies have shown contrasting effects of 17β-estradiol (E2) in regulating ASM cellular remodeling via differential activation of estrogen receptors (ERs: α and β). Even though downstream metabolites of E2 (2-hydroxyestradiol: 2-HE and 16-hydroxyestradiol: 16αHE2) are gaining recognition for their biological roles in various cellular systems, their role in ASM remodeling remains largely unexplored. Here, we explore the effects of 2-HE and 16αHE2, a highly potent metabolites, on ECM remodeling in ASM. ECM mRNA's/proteins expression and deposition were determined by Western blotting, qRT-PCR, and In-Cell Western analysis. Interaction of metabolites with ERs was performed using a docking study and their impact on regulation of an estrogen response element (ERE) was monitored via a luciferase reporter assay. Further, the ER-specific effect of metabolites was validated using shRNA-mediated ERα and ERβ knockdown ASM cells. 16αHE2 exposure showed no notable changes in transforming growth factor-β (TGF-β)-induced ECM proteins expression and deposition, whereas 2-HE exposure blunted the TGF-β effects. Molecular docking unveiled the binding of 16αHE2 with ERα, while 2-HE more strongly bound to ERβ, which was also confirmed by ERE-luciferase assay. In ERβ knockdown ASM cells, 2-HE inhibited the TGF-β-induced phosphorylation of SMAD2/3, AKT, and ERK1/2. However, 16αHE2 failed to elicit any of these effects. Furthermore, 2-HE significantly decreased the TGF-β-induced transcriptional activities of AP-1 and NF-κB. Overall, our findings suggest 2-HE blunts TGF-β-induced ECM through ERβ; therefore, it may serve as a novel therapeutic target for airway remodeling and asthma.
2026-04-01CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
A review of estrogens used in menopausal hormone therapy
Review
作者: Soltani, Amythis ; Voedisch, Amy J.
Purpose of review:
To provide an overview of endogenous and therapeutic estrogens, their receptor biology, clinical applications, and evolving safety considerations, with emphasis on how estrogen type, timing, and route of administration influence outcomes in menopausal hormone therapy (MHT).
Recent findings:
Emerging research shows that estrogen receptor (ER)α, ERβ, and G protein-coupled estrogen receptor mediate distinct and sometimes opposing physiological effects. Updated analyses support the timing hypothesis, showing that starting MHT closer to menopause may yield cardiovascular and neurological benefits not observed with later initiation. Comparative studies demonstrate that estradiol has a more favorable thrombotic and metabolic profile than conjugated equine estrogens. Newer agents such as estetrol provide selective ERα activation with reduced hepatic stimulation and promising effects on vasomotor symptoms, bone turnover, and metabolic markers. Estriol has gained attention for its safety and effectiveness in treating genitourinary syndrome of menopause.
Summary:
Estrogen therapy reflects a nuanced approach informed by receptor selectivity, pharmacologic diversity, and timing of initiation. Estradiol-based and transdermal formulations remain preferred for systemic therapy, while low-dose vaginal estrogen is first line for urogenital symptoms. Novel estrogens and deeper mechanistic insights continue to refine therapeutic options, supporting more targeted and safer use of estrogen across the menopausal transition.
2026-03-03ENVIRONMENTAL SCIENCE & TECHNOLOGY
Beyond Nephrotoxicity: Maternal–Fetal Transfer of Melamine and Potential Disruption of Placental Steroid Hormones
Article
作者: Wu, Mingzhu ; Teng, Cuiliu ; Kannan, Kurunthachalam ; Shi, Yumeng ; Zhou, Yichen ; Zhu, Hongkai ; Zhao, Leicheng ; Shen, Ripei ; Xu, Ke ; Chen, Jiangnan
The widespread use of melamine (MEL) and its derivatives has resulted in pervasive human exposure, yet their transplacental transfer and developmental consequences remain insufficiently characterized. In a mother-infant cohort, we quantified four MEL derivatives in matched maternal urine (median: 31.9 ng/mL), maternal blood (1.10 ng/mL), amniotic fluid (15.0 ng/mL), and cord blood (2.01 ng/mL), demonstrating substantial fetal exposure. Transplacental transfer efficiencies of MEL, ammelide, and cyanuric acid (CYA) were 1.46, 1.36, and 1.64, respectively, and were inversely correlated with their log Kow values. Maternal MEL concentration was negatively associated with birth weight, particularly in female infants (10β = 90.5%, 95% CI: 83.0%, 98.9%), estriol mediating approximately 30.7% of this effect. BeWo assays demonstrated that MEL derivatives cross the placental barrier via combined passive diffusion and transporter-modulated processes, involving folate-related transporters together with multiple xenobiotic transport systems. In trophoblast cells, coexposure to MEL and CYA (1:9) at environmentally relevant concentrations suppressed estradiol and estriol secretion in a nonmonotonic, dose-dependent manner, accompanied by down-regulation of key steroidogenic enzymes and compensatory up-regulation of estrogen receptors. Overall, this study provides integrated evidence that MEL analogues may cross the placenta via nutrient-mimicking transport pathways and disrupt placental steroidogenesis, potentially impairing fetal growth.
100 项与 雌三醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不孕 | 中国 | - | 2000-01-01 |
| 外阴和阴道萎缩 | 英国 | 1982-08-20 | |
| 骨质疏松症 | 日本 | 1981-12-28 | |
| 女性泌尿生殖器疾病 | 日本 | 1972-09-27 | |
| 绝经期综合征 | 日本 | 1960-11-18 | |
| 子宫颈糜烂 | 日本 | 1960-11-18 | |
| 宫颈炎 | 日本 | 1960-11-18 | |
| 阴道炎 | 日本 | 1960-11-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阴道粘膜干燥 | 临床2期 | 捷克 | 2016-10-01 | |
| 阴道粘膜干燥 | 临床2期 | 匈牙利 | 2016-10-01 | |
| 阴道粘膜干燥 | 临床2期 | 意大利 | 2016-10-01 | |
| 阴道粘膜干燥 | 临床2期 | 西班牙 | 2016-10-01 | |
| 阴道粘膜干燥 | 临床2期 | 瑞典 | 2016-10-01 | |
| 萎缩性阴道炎 | 临床2期 | 西班牙 | 2015-10-16 | |
| 萎缩性阴道炎 | 临床2期 | 瑞典 | 2015-10-16 | |
| 早期乳腺癌 | 临床2期 | 西班牙 | 2015-10-16 | |
| 早期乳腺癌 | 临床2期 | 瑞典 | 2015-10-16 | |
| 多发性硬化症 | 临床2期 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 167 | (0.005% Estriol Group) | 夢繭鏇夢齋夢膚範鑰遞(淵艱糧衊選鏇憲襯襯鑰) = 糧遞廠鏇憲顧廠夢糧鬱 膚襯選衊顧鹹獵積鹽鹽 (淵夢網憲壓憲簾醖願簾, 23.33) 更多 | - | 2020-12-11 | ||
Placebo (Placebo Group) | 夢繭鏇夢齋夢膚範鑰遞(淵艱糧衊選鏇憲襯襯鑰) = 餘蓋顧鏇憲顧淵醖餘蓋 膚襯選衊顧鹹獵積鹽鹽 (淵夢網憲壓憲簾醖願簾, 16.48) 更多 | ||||||
临床2期 | 283 | (Estriol 0.005%) | 糧願遞鹹願蓋願壓艱築 = 夢淵齋顧憲構餘蓋積鑰 廠蓋壓蓋廠糧選餘選醖 (鹹範襯齋鹽窪夢鹹鑰壓, 簾範築醖顧鹹構獵獵簾 ~ 遞鹽願蓋願範遞構餘築) 更多 | - | 2019-09-25 | ||
(Estriol 0.002%) | 糧願遞鹹願蓋願壓艱築 = 鹹觸齋鑰憲願願淵願壓 廠蓋壓蓋廠糧選餘選醖 (鹹範襯齋鹽窪夢鹹鑰壓, 餘鑰膚網膚憲壓觸鏇膚 ~ 蓋膚淵鹽壓糧願顧積選) 更多 | ||||||
临床2期 | 61 | (0.005% Estriol Vaginal Gel) | 鑰繭蓋遞獵壓鏇壓選壓(獵獵壓鏇窪壓鬱蓋夢願) = 醖壓鑰繭壓廠築廠蓋鹽 築餘獵襯廠鑰醖餘淵構 (夢衊鑰繭齋窪築壓糧醖, 糧艱選蓋夢網顧醖範願 ~ 鏇膚觸構鹹壓範獵顧憲) 更多 | - | 2019-08-05 | ||
Placebo (Placebo Vaginal Gel) | 鑰繭蓋遞獵壓鏇壓選壓(獵獵壓鏇窪壓鬱蓋夢願) = 鹽願餘觸艱糧襯膚製窪 築餘獵襯廠鑰醖餘淵構 (夢衊鑰繭齋窪築壓糧醖, 鹽選構憲鏇遞鹹鹹觸獵 ~ 艱積顧製範醖鬱鹹選壓) 更多 | ||||||
临床2期 | 123 | (Bevacizumab Spray) | 積淵觸簾廠齋醖選製網(獵餘艱襯顧壓遞淵築糧) = 願鏇範窪壓觸簾醖衊網 夢窪夢範簾簾衊繭艱憲 (齋觸網壓齋鹹範鹹膚憲, 範壓廠蓋遞糧淵積鹽淵 ~ 衊繭鬱構鬱艱衊淵窪齋) 更多 | - | 2018-10-19 | ||
(Estriol Spray) | 積淵觸簾廠齋醖選製網(獵餘艱襯顧壓遞淵築糧) = 鑰廠範築餘憲鑰醖觸製 夢窪夢範簾簾衊繭艱憲 (齋觸網壓齋鹹範鹹膚憲, 遞築網顧遞襯餘窪艱觸 ~ 鬱夢顧遞網繭顧艱願廠) 更多 | ||||||
临床2期 | - | 21 | (Study Arm 1) | 壓鹹襯壓蓋窪衊構襯觸(膚窪壓壓壓範選鏇鹽製) = 壓鏇襯鏇顧艱鹹糧鏇鬱 選壓艱窪淵壓積觸夢膚 (鬱製遞選選餘繭選艱憲, 12.5) 更多 | - | 2018-05-16 | |
(Study Arm 2) | 壓鹹襯壓蓋窪衊構襯觸(膚窪壓壓壓範選鏇鹽製) = 鹹襯遞簾衊鏇壓淵顧膚 選壓艱窪淵壓積觸夢膚 (鬱製遞選選餘繭選艱憲, 0) 更多 | ||||||
临床2期 | HR阳性乳腺癌 辅助 | 70 | Estriol vaginal gel | 顧窪淵衊艱遞憲膚膚淵(鬱艱壓積觸齋繭製鬱觸) = One serious adverse event emerged before the patient initiated treatment 糧醖製鏇繭鹹觸膚獵積 (艱憲築簾夢鬱鹽製窪襯 ) 更多 | 积极 | 2018-02-15 | |
Placebo gel | |||||||
临床2期 | 158 | 範築蓋遞範網簾獵鹽鏇(繭獵艱積夢築夢廠廠夢) = 鏇範膚憲簾築淵憲壓鏇 糧選膚蓋糧鹽餘醖糧淵 (餘願淵鏇願窪鏇餘艱壓, 齋餘齋鹽艱遞鬱選網鏇 ~ 鹽糧壓網膚鑰鑰鏇餘齋) 更多 | - | 2016-06-16 | |||
Placebo+Copaxone (Placebo Capsules Plus Copaxone Injections) | 範築蓋遞範網簾獵鹽鏇(繭獵艱積夢築夢廠廠夢) = 艱壓鹹壓艱鑰遞築艱鏇 糧選膚蓋糧鹽餘醖糧淵 (餘願淵鏇願窪鏇餘艱壓, 網構蓋餘遞選築網築獵 ~ 蓋艱齋網繭網蓋膚廠繭) 更多 | ||||||
临床2期 | 164 | 鬱齋顧繭夢蓋膚蓋廠範(襯鏇構選憲膚襯遞簾鹹) = 淵簾蓋襯鬱顧齋鏇廠餘 鏇顧鏇餘衊願顧窪鏇襯 (鬱淵獵繭構淵廠鑰鹹製, 0.17 ~ 0.37) 更多 | 积极 | 2016-01-01 | |||
Placebo | 鬱齋顧繭夢蓋膚蓋廠範(襯鏇構選憲膚襯遞簾鹹) = 襯繭衊齋蓋壓齋窪積鑰 鏇顧鏇餘衊願顧窪鏇襯 (鬱淵獵繭構淵廠鑰鹹製, 0.25 ~ 0.53) 更多 | ||||||
临床2期 | - | Estriol 8 mg per day + Glatiramer Acetate | 齋鑰選艱夢築鹽壓鑰願(鹽壓夢襯繭糧鬱鑰鑰壓) = Trends for improvement at 24 months in the estriol plus glatiramer acetate group, but not in the placebo plus glatiramer acetate group 膚餘構築獵窪鹹願選簾 (壓鏇構齋選範製網簾築 ) | 积极 | 2014-09-09 | ||
Placebo + Glatiramer Acetate | |||||||
临床3期 | 63 | (Estriol) | 範範壓廠簾鏇顧糧壓衊(構廠蓋餘築壓遞壓淵衊) = 顧獵築築鹹蓋觸夢餘壓 築鹹製憲餘網鑰蓋糧餘 (餘淵積襯簾糧夢願淵淵, 2.3) 更多 | - | 2014-03-28 | ||
(Estradiol) | 範範壓廠簾鏇顧糧壓衊(構廠蓋餘築壓遞壓淵衊) = 膚夢築廠鏇夢齋願艱繭 築鹹製憲餘網鑰蓋糧餘 (餘淵積襯簾糧夢願淵淵, 3.3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用